Overview

Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer

Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
0
Participant gender:
Female
Summary
RATIONALE: It is not yet known if treatment for recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer is more effective if it is begun when blood levels of CA 125 become elevated rather than waiting for other indicators of disease recurrence. PURPOSE: This randomized phase III trial is studying early chemotherapy based on blood levels of CA 125 alone to see how well it works compared to chemotherapy based on conventional clinical indicators in patients with recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Medical Research Council
Collaborator:
European Organisation for Research and Treatment of Cancer - EORTC
Criteria
DISEASE CHARACTERISTICS:

- Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal
cancer

- Achieved complete remission with normal CA 125 after first-line
platinum-containing chemotherapy

- Prior participation in the following clinical trials is allowed:

- MRC-ICON2 (carboplatin vs cyclophosphamide, doxorubicin, and cisplatin for
advanced disease)

- MRC-ICON3 (paclitaxel with carboplatin in first-line therapy for advanced
disease)

- MRC-ICON5 (carboplatin and paclitaxel vs triplet and sequential doublet
combinations of chemotherapy)

- No prior participation in MRC-ICON1 (adjuvant chemotherapy for early-stage ovarian
cancer)

PATIENT CHARACTERISTICS:

Age:

- Not specified

Performance status:

- Not specified

Hematopoietic:

- Not specified

Hepatic:

- Not specified

Renal:

- Not specified

Other:

- No prior or concurrent malignancy within the past 5 years that is likely to preclude
study treatment or comparisons except for nonmelanoma skin cancer

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- Not specified

Chemotherapy:

- See Disease Characteristics

Endocrine therapy:

- Not specified

Radiotherapy:

- Not specified

Surgery:

- Not specified